In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. This is an ...
Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...
Bladder cancer is the 4th most prevalent cancer in men, 11th in women and presents one of the highest rates of post-treatment recurrence (70%) among malignancies. Despite its impact on human health, ...
Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results